title: Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration.
abstract: OBJECTIVE
  The purpose of this study was to compare two strategies for retreatment with ranibizumab in exudative age-related macular degeneration.
  
  
  METHODS
  Two series of consecutive patients treated with ranibizumab in a hospital-based department of ophthalmology were analyzed retrospectively: the first series (n = 52), after as-needed reinjections (PRN group) and the second (n = 38) after reinjections according to the Inject and Extend dosing method (IaE group). Patients' baseline characteristics, type of choroidal neovascularization, and Early Treatment Diabetic Retinopathy Study initial and final visual acuity (at 52 ± 4 weeks) were recorded in each group. Groups were compared by the Mann-Whitney U test or Fisher's exact test.
  
  
  RESULTS
  Groups were well balanced at baseline for age (P = 0.58), sex (P = 0.66), laterality (P > 0.99), and initial visual acuity (P = 0.33). At 1 year, the mean gain in visual acuity was greater in the IaE group than in the PRN group (+10.8 ± 8.8 vs. +2.3 ± 17.4 letters, P = 0.036), but eyes in the IaE group were given significantly more injections (7.8 ± 1.3 vs. 5.2 ± 1.9 injections, P < 0.001). The number of follow-up visits attended was similar (8.5 ± 1.1 vs. 8.8 ± 1.5, P = 0.2085).
  
  
  CONCLUSIONS
  Patients reinjected by the IaE dosing method had a far better visual outcome but after more injections.
authors.affiliation: Departement of Ophthalmology, Centre Hospitalier, Orleans, France.
authors.forename: Hassiba
authors.initials: H
authors.lastname: Oubraham
authors.forename: Salomon Y
authors.initials: SY
authors.lastname: Cohen
authors.forename: Sepideh
authors.initials: S
authors.lastname: Samimi
authors.forename: David
authors.initials: D
authors.lastname: Marotte
authors.forename: Ines
authors.initials: I
authors.lastname: Bouzaher
authors.forename: Pierre
authors.initials: P
authors.lastname: Bonicel
authors.forename: Franck
authors.initials: F
authors.lastname: Fajnkuchen
authors.forename: Ramin
authors.initials: R
authors.lastname: Tadayoni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005122:Exudates and Transudates / Q000378:metabolism*; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000150:complications* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D019233:Retreatment; D012189:Retrospective Studies; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab